Vlad Hogenhuis, MD, MBA

Chief Executive Officer @ Chimera Bioengineering

About

Experienced C-level physician executive with a demonstrated record of accomplishment in the biotech and pharmaceuticals industry. Skilled in operations and global P&L management on three continents. Closed 20 transformative +BD deals. Experience in transitioning a company culture towards commercial excellence. Experience in rare diseases, Rheumatology, Oncology, Nephrology, Cardiology, Ophthalmology, Cell and Gene Therapy, CAR/T, mRNA. Overseeing gene therapy and mRNA manufacturing operations. Master of Business Administration (MBA) degree focused in Marketing and Healthcare Management from the Wharton School, and Medical Degree from the University of Leiden, The Netherlands.

Country

United States

City

San Francisco

Industry

Biotechnology

Skill

Start-up Leadership, Start-up Ventures, Board Level, Fundraising, Mergers & Acquisitions (M&A), Methods Engineering, Artificial Intelligence (AI), Pharmaceutical Industry, Lifesciences, Market Access, Pharmaceutical Sales, Healthcare, Product Launch, Cross-functional Team Leadership, Cardiology, Commercialization, Global Marketing, Sales Effectiveness, Managed Care, Marketing Strategy

Experience

Chief Executive Officer

Chimera Bioengineering

2021-11 - Present · 4 yrs 11 mos

South San Francisco

Chimera's mission is to reprogram life to end cancer, using therapies that restore dignity to patients. We do this with next generation, safer and more potent, CAR T therapeutics.

Member Board Of Directors

Rezolute, Inc.

2021-3 - Present · 5 yrs 7 mos

Redwood City, California, United States

Member Board Of Directors

IHP Therapeutics

2020-6 - Present · 6 yrs 4 mos

San Francisco, California, United States

IHP Therapeutics is developing IHP-002, a preclinical drug to prevent VOCs in patients with Sickle cell disease, and is supported by a $10 MM NIH grant and investments from multiple investors.

Founder

Lapene Consulting LLC

2020-5 - Present · 6 yrs 5 mos

San Francisco, California, United States

Consulting for various Companies and VCs (e.g. Third Rock, start ups). Fractional CEO, BD roles. Creation and prioritization of development options, BD and fundraising outreach

CBO and Member Board Of Directors

GATT Technologies

2020-5 - 2023-11 · 3 yrs 7 mos

The Netherlands

Successful medtech exit -- Company acquired by Ethicon in 2023. Developed ETHIZIA, a novel hemostat that effectively stops surgery bleeds in seconds. https://www.prnewswire.com/news-releases/ethicon-introduces-ethizia-hemostatic-sealing-patch-clinically-proven-to-stop-disruptive-bleeding-301989164.html

Chief Operating Officer

Ultragenyx

2018-9 - 2020-6 · 1 yr 10 mos

Novato, CA

Responsible for rare disease product launches, global P&L management, business development and alliance management, and global manufacturing operations including gene therapy and mRNA production

SVP and Global Franchise Head Specialty Care

GlaxoSmithKline

2015-2 - 2018-9 · 3 yrs 8 mos

London, United Kingdom

Responsible for Cardiovascular, Metabolic, Rheumatology, Immunology, Infectious Disease, Oncology, Dermatology and Neuroscience Therapeutic Areas

SVP and Global Franchise Lead Cardiovascular, Metabolic and Neurosciences

GSK

2012-12 - 2015-1 · 2 yrs 2 mos

Brentford, UK

Senior VP and Managing Director

Merck

2011-8 - 2012-12 · 1 yr 5 mos

Brussels, Belgium

Senior VP and Chief Marketing Officer

Merck Sharp & Dohme

2009 - 2011-8 · 2 yrs

Shanghai, China

Senior VP and General Manager

Merck & Co.

2006-8 - 2009-8 · 3 yrs 1 mo

Responsible for all commercial activities of Merck/MSD pharmaceutical products in Neuroscience, Dermatology and Ophthalmology, comprising $1.7 B in annnual sales; responsible for global commercialization of late stage developmental (phase III) Neuroscience, Dermatology, and Ophthalmology products.